Status:
NOT_YET_RECRUITING
Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients
Lead Sponsor:
Assiut University
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To detect value of F-18FDG PET/CT as a non-invasive method for the prediction of EGFR mutations in lung cancer patients.
Detailed Description
* Globally, lung cancer cases and deaths are rising. In 2018, GLOBOCAN estimated 2.09 million new cases (11.6% of total cancer cases) and 1.76 million deaths (18.4% of total cancer deaths). It is the ...
Eligibility Criteria
Inclusion
- NSCLC patients who underwent EGFR mutation testing.
- All patients ≥ 18 years.
Exclusion
- Time interval between EGFR sampling and PET/CT more than 1 month.
- Patients had been treated before sampling for the gene alteration analysis
- Patients with glucose level \< 200 mg/dl.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06520189
Start Date
October 1 2024
End Date
October 1 2028
Last Update
July 25 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.